PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

Background: Cabozantinib is approved, in various settings, for the treatment of renal cell
carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been …

Introduction We conducted a systematic literature review to identify evidence for use of
vascular endothelial growth factor (VEGF)-targeted (anti-VEGF) treatment in patients with …

Background: First-line therapies based on immune-checkpoint inhibitors (ICIs) significantly
improved survival of metastatic renal cell carcinoma (mRCC) patients. Cabozantinib was …

The therapeutic sc" enario of metastatic renal cell cancer (mRCC) has noticeably increased,
ranging from the most studied molecular target therapies to those most recently introduced …

The recent approval of immune checkpoint inhibitor (ICI)-based combinations has redefined
the first-line standard of care of metastatic renal cell carcinoma (mRCC) patients. Although …

Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on
the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns …

Background The INMUNOSUN trial had the objective of prospectively evaluating the efficacy
and safety of sunitinib as a pure second-line treatment in patients with metastatic renal cell …

Background Nivolumab plus ipilimumab combination therapy is one of the standard
therapies for untreated renal cell carcinoma patients with an International Metastatic Renal …

Real-world cabozantinib use has increased since its approval to treat patients with
advanced renal cell carcinoma (RCC) in 2016. We reviewed cabozantinib use in real-world …